House dust mite regulatory update

Japan approved an NDA from Torii for Miticure house dust mite (HDM) sublingual tablets to treat allergic rhinitis caused by HDM in patients ages 12-64. Torii will announce its launch plans for Miticure after the price is established by Japan’s National Health Insurance (NHI). The approval triggered an undisclosed milestone payment to Torii, which has exclusive, Japanese rights to the product from ALK-Abello (see BioCentury, Jan. 31, 2011). Torii also began a Japanese Phase III trial of Miticure in about 400 patients ages 5-11. ...